Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study

Mar 20, 2025Diabetes, obesity & metabolism

Health outcomes in adults with obesity treated with tirzepatide versus weight-loss surgery

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The incidence of all-cause mortality was 0.19 per 100 person-years in the tirzepatide group compared with 0.57 in the bariatric metabolic surgery group.

Tirzepatide is associated with a significantly lower risk of all-cause mortality compared to bariatric metabolic surgery, with a hazard ratio of 0.311.
The risk of major adverse cardiovascular events (MACEs) was reduced in the tirzepatide group, with a hazard ratio of 0.743.
Tirzepatide also lowered the risk of major adverse kidney events (MAKEs) with a hazard ratio of 0.375.
Mortality benefits and reductions in MACEs and MAKEs were consistent across various age groups, genders, and BMI categories.
Preliminary findings suggest that tirzepatide may serve as an effective non-surgical alternative to bariatric metabolic surgery.

AI simplified

AIMS: This real-world study compared clinical outcomes between tirzepatide treatment and bariatric metabolic surgery (BMS) in adults with obesity.

METHODS: This retrospective cohort study used the TriNetX network to identify adults with a body mass index (BMI) ≥ 30 kg/m. Patients initiating tirzepatide treatment were compared with those undergoing BMS. The primary outcome was all-cause mortality, while secondary outcomes included major adverse cardiovascular events (MACEs) and major adverse kidney events (MAKEs). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated, and stratified analyses were performed based on age, sex and BMI categories. 2

RESULTS: After exclusions and 1:1 propensity score matching (PSM), 84 884 matched pairs were analysed. The incidence of all-cause mortality was 0.19 per 100 person-years in the tirzepatide group compared with 0.57 in the BMS group. Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with BMS (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001). The mortality benefits were consistent across age groups, genders and BMI categories. Tirzepatide also reduced the risk of MACEs (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001) and MAKEs (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001). Stratified analyses demonstrated significant reductions in primary and secondary outcomes across most categories.

CONCLUSION: Tirzepatide demonstrated superior clinical outcomes compared with BMS in adults with obesity, including significant reductions in all-cause mortality, MACEs and MAKEs. These findings suggest that tirzepatide may serve as an effective non-surgical alternative to BMS, with broad applicability across diverse patient populations.

Full Text

Full text is available at the source.

View full text ↗

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief